nach oben

Die Onkologie

Erschienen in:

30.07.2018 | Sarkome | CME

Update zu uterinen Sarkomen

verfasst von: Dr. med. Helmut Plett, Mareike Bommert, Beyhan Ataseven, Florian Heitz, Philipp Harter

Erschienen in: Die Onkologie | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Uterine Sarkome bilden eine inhomogene Gruppe seltener Tumoren der Uterusmuskulatur. Es sind meist aggressive Neoplasien, die vom uterinen Bindegewebe oder vom endometrialen Stroma ausgehen. Histologisch werden folgende Subtypen unterschieden: das Leiomyosarkom (LMS), das low-grade endometriale Stromasarkom (LG-ESS) und das high-grade endometriale Stromasarkom (HG-ESS) sowie das undifferenzierte Stromasarkom (UES). Die Inzidenz liegt bei 0,5–3,3 pro 100.000 Frauen pro Jahr; insgesamt bilden sie mit 1–2 % nur einen kleinen Anteil der uterinen Malignome. Eine andere Kategorie bilden uterine Sarkome gemischten Ursprungs, wie Adenosarkome, Karzinosarkome (maligne Müller-Mischtumoren) und andere heterologe Sarkome (z. B. Chondrosarkome, Liposarkome, Fibrosarkome etc.). Im Beitrag wird auf das spezifische Management der häufigen Entitäten (LMS, LG-ESS, HG-ESS und UES) Bezug genommen. Im August 2015 wurde die erste Version einer S2k-Leitlinie zu uterinen Sarkomen herausgegeben.

Brooks SE, Zhan M, Cote T, Baquet CR (2004) Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 93:204–208CrossRefPubMed

D’Angelo E, Prat J (2010) Uterine sarcomas: a review. Gynecol Oncol 116:131–139CrossRefPubMed

Pietzner K, Buttmann-Schweiger N, Sehouli J, Kraywinkel K (2017) Incidence patterns and survival of gynecological sarcoma in Germany: analysis of population-based cancer registry data on 1066 women. Int J Gynecol Cancer 28:134. https://doi.org/10.1097/IGC.0000000000001128 CrossRef

Pelmus M, Penault-Llorca F, Guillou L, Collin F, Bertrand G, Trassard M, Leroux A, Floquet A, Stoeckle E, Thomas L, MacGrogan G (2009) Prognostic factors in early-stage leiomyosarcoma of the uterus. Int J Gynecol Cancer 19:385–390CrossRefPubMed

Seagle B‑LL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S (2017) Prognosis and treatment of uterine leiomyosarcoma: a national cancer database study. Gynecol Oncol 145:61–70CrossRefPubMed

FDA_Safety_Communication_Laparoscopic_Morcellation_Hysterectomy.pdf. https://www.basg.gv.at/fileadmin/_migrated/content_uploads/FDA_Safety_Communication_Laparoscopic_Morcellation_Hysterectomy.pdf. Zugegriffen: 14.12.2017

Park J‑Y, Park S‑K, Kim D‑Y, Kim J‑H, Kim Y‑M, Kim Y‑T, Nam J‑H (2011) The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol 122:255–259CrossRefPubMed

Perri T, Korach J, Sadetzki S, Oberman B, Fridman E, Ben-Baruch G (2009) Uterine leiomyosarcoma: does the primary surgical procedure matter? Int J Gynecol Cancer 19:257–260CrossRefPubMed

Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS (2003) Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 91:209–212CrossRefPubMed

10.

Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhommé C, Rey A (2013) A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol 24:1099–1104CrossRefPubMed

11.

Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, Teodorovic I, Vergote I, Vermorken JB, European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44:808–818CrossRefPubMed

12.

Hensley ML, Ishill N, Soslow R, Larkin J, Abu-Rustum N, Sabbatini P, Konner J, Tew W, Spriggs D, Aghajanian CA (2009) Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 112:563–567CrossRefPubMed

13.

Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Soslow RA, Baker LH (2013) Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 119:1555–1561CrossRefPubMed

14.

Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, Beecham J, Park R, Silverberg S (1985) A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 3:1240–1245CrossRefPubMed

15.

Bernstein-Molho R, Grisaro D, Soyfer V, Safra T, Merimsky O (2010) Metastatic uterine leiomyosarcomas: a single-institution experience. Int J Gynecol Cancer 20:255–260CrossRefPubMed

16.

Giuntoli RL, Garrett-Mayer E, Bristow RE, Gostout BS (2007) Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol 106:82–88CrossRefPubMed

17.

Seddon B, Scurr M, Jones RL, Wood Z, Propert-Lewis C, Fisher C, Flanagan A, Sunkersing J, A’Hern R, Whelan J, Judson I (2015) A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin Sarcoma Res 5:13CrossRefPubMedPubMedCentral

18.

Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi H‑M, Beare S (2017) Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 18:1397–1410CrossRefPubMedPubMedCentral

19.

Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected. J Clin Oncol 25:2755–2763CrossRefPubMed

20.

Harter P, Sehouli J, Reuss A, Baumann K, Hanker L, Kimmig R, Schröder W, Burges A, Gropp-Meier M, Kurzeder C, Mahner S, Canzler U, Lück H‑J, Meier W, Fehm T, du Bois A (2016) Phase II study evaluating pegLiposomal doxorubicin and carboplatin combination chemotherapy in gynecologic sarcomas and mixed epithelial-mesenchymal tumors A phase II protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie study group (AGO-GYN 7). Int J Gynecol Cancer 26:1636–1641CrossRefPubMed

21.

Gadducci A, Guerrieri ME (2015) Pharmacological treatment for uterine leiomyosarcomas. Expert Opin Pharmacother 16:335–346CrossRefPubMed

22.

Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD (2017) Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol 146:531–537CrossRefPubMedPubMedCentral

23.

Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized Multicenter clinical trial. J Clin Oncol 34:786–793CrossRefPubMed

24.

Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, Cupissol D, Selle F, Isambert N, Piperno-Neumann S, Thyss A, Bertucci F, Bompas E, Alexandre J, Collard O, Lavau-Denes S, Soulié P, Toulmonde M, Le Cesne A, Lacas B, Duffaud F, French Sarcoma Group (2015) Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol 16:457–464CrossRefPubMed

25.

van der Graaf WTA, Blay J‑Y, Chawla SP, Kim D‑W, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P, Soft Tissue EORTC, EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886CrossRefPubMed

26.

Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK (2016) Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 388:488–497CrossRefPubMedPubMedCentral

27.

Ali RH, Rouzbahman M (2015) Endometrial stromal tumours revisited: an update based on the 2014 WHO classification. J Clin Pathol 68:325–332CrossRefPubMed

28.

Chan JK, Kawar NM, Shin JY, Osann K, Chen L‑M, Powell CB, Kapp DS (2008) Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 99:1210–1215CrossRefPubMedPubMedCentral

29.

Barney B, Tward JD, Skidmore T, Gaffney DK (2009) Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer 19:1232–1238CrossRefPubMed

30.

Seagle B‑LL, Shilpi A, Buchanan S, Goodman C, Shahabi S (2017) Low-grade and high-grade endometrial stromal sarcoma: A National Cancer Database study. Gynecol Oncol 146:254–262CrossRefPubMed

31.

Bai H, Yang J, Cao D, Huang H, Xiang Y, Wu M, Cui Q, Chen J, Lang J, Shen K (2014) Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases. Gynecol Oncol 132:654–660CrossRefPubMed

32.

Signorelli M, Fruscio R, Dell’Anna T, Buda A, Giuliani D, Ceppi L, Milani R (2010) Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: an analysis of 19 cases and a literature review. Int J Gynecol Cancer 20:1363–1366PubMed

33.

Chu MC, Mor G, Lim C, Zheng W, Parkash V, Schwartz PE (2003) Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol 90:170–176CrossRefPubMed

34.

Gadducci A, Cosio S, Romanini A, Genazzani AR (2008) The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 65:129–142CrossRefPubMed

35.

Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I (2009) Clinical management of uterine sarcomas. Lancet Oncol 10:1188–1198CrossRefPubMed

36.

Pautier P, Nam EJ, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray-Coquard I (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus. Int J Gynecol Cancer 24:S73–S77CrossRefPubMed

37.

Schick U, Bolukbasi Y, Thariat J, Abdah-Bortnyak R, Kuten A, Igdem S, Caglar H, Ozsaran Z, Lössl K, Schleicher U, Zwahlen D, Villette S, Vees H (2012) Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study. Int J Radiat Oncol Biol Phys 82:e757–e763CrossRefPubMed

38.

Leath CA, Huh WK, Hyde J, Cohn DE, Resnick KE, Taylor NP, Powell MA, Mutch DG, Bradley WH, Geller MA, Argenta PA, Gold MA (2007) A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 105:630–634CrossRefPubMed

39.

Lewis N, Soslow RA, Delair DF, Park KJ, Murali R, Hollmann TJ, Davidson B, Micci F, Panagopoulos I, Hoang LN, Arias-Stella JA, Oliva E, Young RH, Hensley ML, Leitao MM, Hameed M, Benayed R, Ladanyi M, Frosina D, Jungbluth AA, Antonescu CR, Chiang S (2018) ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Mod Pathol 31(4):674. https://doi.org/10.1038/modpathol.2017.162 CrossRefPubMed

40.

Caudell JJ, Deavers MT, Slomovitz BM, Lu KH, Broaddus RR, Gershenson DM, Ramondetta LM (2005) Imatinib mesylate (gleevec) – targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol 13:167–170CrossRefPubMed

41.

Coosemans A, Nik SA, Caluwaerts S, Lambin S, Verbist G, Van Bree R, Schelfhout V, de Jonge E, Dalle I, Jacomen G, Cassiman JJ, Moerman P, Vergote I, Amant F (2007) Upregulation of Wilms’ tumour gene 1 (WT1) in uterine sarcomas. Eur J Cancer 43:1630–1637CrossRefPubMed

Titel: Update zu uterinen Sarkomen
verfasst von: Dr. med. Helmut Plett
Mareike Bommert
Beyhan Ataseven
Florian Heitz
Philipp Harter
Publikationsdatum: 30.07.2018
Verlag: Springer Medizin
Schlagwörter: Sarkome
Zytostatische Therapie
Uterussarkom
Erschienen in: Die Onkologie / Ausgabe 9/2018
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-018-0444-6

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Update zu uterinen Sarkomen

Zusammenfassung

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Update zur systemischen Therapie bei fortgeschrittenem hepatozellulärem Karzinom

Hepatozelluläres Karzinom

Das hepatozelluläre Karzinom – pathologische und molekularpathologische Diagnostik

Hepatozelluläres Karzinom – Stellenwert von Resektion, Lebertransplantation und Immunsuppression

Bildgeführte radiologische Interventionen beim HCC

Epidemiologie des hepatozellulären Karzinoms in Deutschland

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie